GRWD1 as a Novel Signature and It Down Regulates IFN in Skin Aging
Cell Biochemistry and Function · 2026-07 · 44 (7)
DOI: 10.1002/cbf.70258 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biochemistry and Function, online erschienen am 13.07.2026. Verfasst von Fei Tan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China. Hauptthemen laut MEDLINE: Skin Aging, Interferons, Down-Regulation. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The Shanghai Shen Kang Clinical Technology Promotion Program (No. SHDC12026111) and The Xi'an Municipal Health Commission General Research Project (No. 2026ms0….
Abstract (Originalsprache)
Deep mining of the molecular mechanisms underlying skin aging is critical for the development of novel therapeutic targets. The aim of this study was to explore potential key signatures and underlying mechanisms in skin aging. Bioinformatics tools were used to evaluate the differentially expressed genes (DEGs), perform enrichment analysis, and construct protein‐protein interaction networks on datasets. The hub genes were identified using Cytoscape software and then confirmed by qRT‐PCR and Western Blot in vitro. We focused on the possible roles of GRWD1. GRWD1 expression were suppressed in senescence model of HDF. After GRWD1 overexpression by lentivirus in primary human dermal Fibroblasts (HDF), transcriptome sequencing (RNA‐seq) was performed. GRWD1 has influence on the inflammation and immune responses. IFN signaling pathway genes significant increase in senescence HDF. When GRWD1 overexpressed, decreased expression of IFN pathway is validated. Besides, age‐related markers p16, IL‐6, and IL‐8 expression decreased and Lamin B expression also increased. It was also proved after GRWD1 knockdown. GRWD1 was identified as a novel signature in skin aging. GRWD1 directly interact with IRF3. GRWD1 overexpression can down regulate IFN signaling pathway key genes expression, further diminish IFN aging‐inducing effects. GRWD1 alleviates skin inflammatory responses by suppressing IRF3‐mediated IFN pathway activation. Our findings suggest that GRWD1 may serve as a molecular biomarker and further as a potential therapeutic target for skin aging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Skin Disease Hospital, School of Medicine, Tongji University, Shanghai, China.
- Shanghai Skin Disease Clinical College, The Fifth Clinical Medical College, Anhui Medical University, Shanghai Skin Disease Hospital, Shanghai, China.
- Department of Ophthalmology of Tongji Hospital and Laboratory of Clinical and Visual Sciences of Tongji Eye Institute, School of Medicine, Tongji University, Shanghai, China.
- Department of General Practice, Xi'an Central Hospital, Xi'an, China.
- School of Public Health and General Medicine, and Department of Cell Biology and Medical Genetics, School of Medicine, Tongji University, Shanghai, China.
ORCID-Profile: Juan Wang
Förderung
- The Shanghai Shen Kang Clinical Technology Promotion Program (No. SHDC12026111) and The Xi'an Municipal Health Commission General Research Project (No. 2026ms0…
Zitieren
APA
Tan, F., Wang, Y., Xu, P., Li, Y., Yan, Y., Gao, Y., Hu, X., Shen, M., Wang, Q., & Wang, J. (2026). GRWD1 as a Novel Signature and It Down Regulates IFN in Skin Aging. Cell Biochemistry and Function, 44(7). https://doi.org/10.1002/cbf.70258
Vancouver
Tan F, Wang Y, Xu P, Li Y, Yan Y, Gao Y, et al. GRWD1 as a Novel Signature and It Down Regulates IFN in Skin Aging. Cell Biochemistry and Function. 2026;44(7). doi:10.1002/cbf.70258
BibTeX
@article{Tan2026,
author = {Tan, Fei and Wang, Yaoqun and Xu, Peng and Li, Yunjin and Yan, Yichen and Gao, Yutong and Hu, Xiaoping and Shen, Mengyuan and Wang, Qixia and Wang, Juan},
title = {GRWD1 as a Novel Signature and It Down Regulates IFN in Skin Aging},
journal = {Cell Biochemistry and Function},
year = {2026},
volume = {44},
number = {7},
doi = {10.1002/cbf.70258}
}
EUVIMED